More bad news for CD47 as response rates in Aspen-06 wane, and the company turns to a subgroup.

Earnings season begins again, while big readouts loom for ALX and Fibrogen.

But investors don't fancy the company's chances, now seeing Aspen-06 as a fluke.

More details on cardiovascular events with the group’s anti-CD47 project comforted analysts, but shares still fell 10%.

As the dust settles on ASCO the weekend’s immediate winners and losers emerge.

Despite magrolimab’s latest flop, efforts to target CD47 continue.

ALX Oncology claims the first ever success for a CD47 inhibitor in a global randomised solid tumour study.